Online inquiry

IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12106MR)

This product GTTS-WQ12106MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12106MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15289MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ13512MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ6371MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ14486MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ8131MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ5958MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ15550MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ2988MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Angiocept
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW